Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin
Business Wire•08/10/2026•09:15 ET
0
Key Highlights
- ➤Simulations Plus (SLP) announces funded partnership with global pharmaceutical company
- ➤Turin will explore mechanistic QSP model structures at scale within an active development program
- ➤Partnership targets faster QSP model building and evaluation for broader MIDD use
- ➤Pharmaceutical partner will use Turin in a hosted environment with Simulations Plus scientific support
- ➤Collaboration is intended to expand rapidly into additional therapeutic development programs
Expert Statements
Shawn O’Connor, Chief Executive Officer of Simulations Plus
“QSP can provide powerful insight into complex biological systems, but the time and expertise required to build and evaluate these models has historically limited where and when they can be applied”
Shawn O’Connor, Chief Executive Officer of Simulations Plus
“Turin is designed to break down that barrier and make QSP practical for a broader range of development decisions.”
Shawn O’Connor, Chief Executive Officer of Simulations Plus
“Working alongside a leading pharmaceutical organization allows us to tailor this approach to meaningful challenges in a real-world development setting while continuing to advance the scientific capabilities of the engine.”
Simulations Plus Announces Funded Partnership with Global Pharmaceutical Company to Advance AI-Enabled QSP Model Development with Turin
Collaboration will apply Turin to explore mechanistic QSP model structures at scale and bring insights to development decisions where traditional modeling timelines have limited their use
Get started
Create a free account to read the full story.